Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers

Current Rheumatology Reports

Volumn 8, Issue 2, 2006, Pages 131-137

  Hummers, Laura K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN 1; VASCULOTROPIN;

ANGIOGENESIS; CELL DAMAGE; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOTHELIUM; ENDOTHELIUM CELL; FIBRINOLYSIS; FOLLOW UP; HUMAN; MICROVASCULATURE; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; VASCULAR DISEASE; BLOOD; DISEASE COURSE; MICROCIRCULATION; PROGNOSIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; MICROCIRCULATION; PROGNOSIS; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 33646903472     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0053-z     Document Type: Review

References (55)

1. Ungerer RG, Tashkin DP, Furst D, et al.: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983, 75:65-74.
2. ter Borg EJ, Piersma-Wichers G, Smit AJ, et al.: Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 1994, 24:40-47.
3. Ohtsuka T, Hasegawa A, Nakano A, et al.: Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis. Int J Dermatol 1997, 36:116-122.
4. Ong YY, Nikoloutsopoulos T, Bond CP, et al.: Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998, 16:81-86.
5. Steen V, Medsger TA, Jr.: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522. This case-control study looked retrospectively at clinical predictors of PAH among patients with limited scleroderma. They found that there was a linear decline in diffusing capacity years preceding the diagnosis of PAH.
6. Medsger TA, Jr.: Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000, 12:545-548.
7. Medsger TA Jr., Silman AJ, Steen VD, et al.: A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999, 26:2159-2167.
8. Clements PJ, Wong WK, Hurwitz EL, et al.: The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum 2001, 44:653-661.
9. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
10. Kahaleh MB: Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004, 22(Suppl 33):S19-S23. This is a nice overview of the history and recent progress in our understanding of the scleroderma vascular disease.
11. Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
12. Kahaleh MB, Fan PS: Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997, 83:32-40.
13. Sgonc R, Gruschwitz MS, Boeck G, et al.: Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
14. Ihn H, Sato S, Fujimoto M, et al.: Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000, 119:203-209.
15. Tamby MC, Chanseaud Y, Humbert M, et al.: Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005, 60:765-772.
16. Kahaleh MB, LeRoy EC: Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmumty 1999, 31:195-214.
17. Gordon JL, Pottinger BE, Woo P, et al.: Plasma von Willebrand factor in connective tissue disease. Ann Rheum Dis 1987, 46:491-492.
18. Marasini B, Cugno M, Bassani C, et al.: Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992, 11:375-382.
19. Blann AD, Illingworth K, Jayson MI: Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993, 20:1325-1330.
20. Herrick AL, Illingworth K, Blann A, et al.: Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996, 55:122-127.
21. Scheja A, Akesson A, Geborek P, et al.: Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001, 3:178-182.
22. Hesselstrand R, Ekman R, Eskilsson J, et al.: Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005, 44:366-371.
23. Vancheeswaran R, Magoulas T, Efrat G, et al.: Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994, 21:1838-1844.
24. Yamane K, Miyauchi T, Suzuki N, et al.: Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
25. Cambrey AD, Harrison NK, Dawes KE, et al.: Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994, 11:439-445.
26. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S: Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VECF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005, 24:111-116.
27. Del Papa N, Colombo G, Fracchiolla N, et al.: Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004, 50:1296-1304. This study examined circulating endothelial cells as a potential marker of vascular damage and circulating endothelial progenitor cells as an indicator of vasculogenesis. Levels of both were noted to be elevated in scleroderma patients.
28. Distler O, Del Rosso A, Giacomelli R, et al.: Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11. Cross-sectional study of multiple regulators of angiogenesis, with correlation with clinical features.
29. Mittag M, Beckheinrich P, Haustein UF: Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001, 81:294-297.
30. Choi JJ, Min DJ, Cho ML, et al.: Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003, 30:1529-1533.
31. Hummers LK, Wigley FM, Simons M: Evidence for Abnormal Angiogenesis in Scleroderma Patients. Arthritis Rheum 2004, 50(Suppl 9):S630.
32. Kawaguchi Y, Harigai M, Hara M, et al.: Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol 2002, 29:1877-1883.
33. Wu MH, Yokozeki H, Takagawa S, et al.: Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004, 11:170-180.
34. Morishita R, Aoki M, Hashiya N, et al.: Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004, 4:199-206.
35. Hebbar M, Peyrat JP, Hornez L, et al.: Increased cocentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43:889-893.
36. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A: Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators lnflamm 2005, 2005:144-149.
37. Kuwana M, Okazaki Y, Yasuoka H, et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610. This study also examined circulating endothelial progenitor cells and found that these cells were lower among scleroderma patients and that they had less ability to differentiate into endothelial cells. This suggests that defective vascular repair mechanisms may contribute to scleroderma vascular disease.
38. Macko RF, Gelber AC, Young BA, et al.: Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002, 29:2565-2570.
39. Kahaleh MB, Osborn I, Leroy EC: Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982, 96:610-913.
40. Kowal-Bielecka O, Kowal K, Lewszuk A, et al.: Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005, 64:484-486.
41. Lau CS, McLaren M, Saniabadi A, Belch JJ: Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993, 22:97-101.
42. Lau CS, Khan F, McLaren M, et al.: The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int 1991, 11:163-168.
43. Goodfield MJ, Orchard MA, Rowell NR: Increased platelet sensitivity to collagen-induced aggregation in whole blood patients with systemic sclerosis. Clin Exp Rheumatol 1988, 6:285-288.
44. Munkvad S, Gram J, Jespersen J: Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Scand J Rheumatol 1989, 18:277-282.
45. Cerinic MM, Valentini G, Sorano GG, et al.: Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003, 32:285-295. Comprehensive look at a cross section of markers of impaired fibrinolysis, endothelial cell activation, and the coagulation cascade.
46. Ames PR, Lupoli S, Alves J, et al.: The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 1997, 36:1045-1550.
47. Herrick AL, Matucci Cerinic M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4-8.
48. D'Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
49. Su B, Mitra S, Gregg H, et al.: Redox regulation of vascular smooth muscle cell differentiation. Circ Res 2001, 89:39-46.
50. Solans R, Motta C, Sola R, et al.: Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 2000, 43:894-900.
51. Simonini G, Cerinic MM, Generini S, et al.: Oxidative stress in Systemic Sclerosis. Mol Cell Biochem 1999, 196:85-91.
52. Montuschi P, Ciabattoni G, Paredi P, et al.: 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998, 158:1524-1527.
53. Stein CM, Tanner SB, Awad JA, et al.: Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996, 39:1146-1150.
54. Volpe A, Biasi D, Caramaschi P, et al.: Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford) 2005, In press.
55. Cope KA, Hummers LK, Wigley FM, et al.: Abnormal exhaled ethane concentrations in scleroderma. Biomarkers 2006, In press.